SIRT5 and breast cancer: Polletta and colleagues found that another SIRT5 inhibitor, MC3482, through modifying ε-N-glutamyl lysine, inhibited succinylation of GLS, thereby promoting autophagy in breast cancer cells and inhibiting tumor initiation and progression 90.